The economic benefit of timely, adequate, and adherence to Parkinson's disease treatment: the Value of Treatment Project 2 by Dodel, R. et al.
The economic benefit of timely, adequate, and adherence to
Parkinson’s disease treatment: the Value of Treatment Project 2
R. Dodela,*, M. Tinellib,*, G. Deuschlc , G. Petersend, W. Oertele and J. Ahmerkamp-B€ohmef
aDepartment of Geriatric Medicine, University Duisburg-Essen, Essen, Germany; bCare Policy Evaluation Centre (CPEC), London
School of Economics and Political Science (LSE), London, UK; cDepartment of Neurology, UKSH, Christian-Albrechts University, Kiel;
dGr€unenthal GmbH, Aachen; eDepartment of Neurology, Philipps-University Marburg, Marburg; and fJung & Parkinson, Die Selbsthilfe
e.V., Bad Camberg, Germany
Keywords:
delayed diagnosis,
economic impact,
inadequate treatment,
lack of adherence,
Parkinson’s disease
Received 24 July 2020
Accepted 2 October 2020
European Journal of
Neurology 2020, 0: 1–10
doi:10.1111/ene.14584
Background: Parkinson’s disease (PD) is a chronic progressive neurolog-
ical disorder with a high psychosocial and economic burden. As part of
the European Brain Council (EBC)-led Value of Treatment project, this
study aimed to capture the economic benefit of timely, adequate, and
adherence to PD treatment.
Methods: The EBC Value of Treatment Initiative combined different
stakeholders to identify unmet needs in the patients’ journey according
to Rotterdam methodology. The economic evaluation focused on three
major topics identified as major gaps: start of treatment; best treatment
for advanced disease; and adherence to treatment. Two separate health-
care systems (Germany and the UK) were chosen. Cost-effectiveness was
determined by using decision-analytical modelling approaches. Effective-
ness was expressed as quality-adjusted life-years (QALYs) gained and
incremental cost-effectiveness ratio (ICER).
Results: Treatment intervention in PD was found to be cost-effective
regardless of the initial health state of the patient receiving the treat-
ment. Cost savings were between -€1000 and €5400 with 0.10 QALY
gain and -€1800 and -€7600 with 0.10 QALY gain for Germany and the
UK, respectively. Treatment remains cost-effective within the National
Institute for Health and Care Excellence thresholds. Availability of ade-
quate treatment to more patients was also found to be cost-effective,
with an ICER of €15,000–€32,600 across country settings. Achieving the
target adherence to treatment would generate cost-savings of €239,000–€
576,000 (Germany) and €917,000–€2,980.000 (UK) for every 1,000
patients treated adequately.
Conclusions: The analyses confirmed that timely, adequate, and adher-
ence to PD treatment will not only improve care of the patients but is
also cost-effective across healthcare systems. Further studies with a dis-
tinct identification of gaps in care are necessary to develop better and
affordable care.
Introduction
Parkinson’s disease (PD) is a chronic progressive dis-
order of the central nervous system, with approxi-
mately 1.42 million (0.2%) people affected in Europe
[1]. It is the second most common neurodegenerative
disorder after Alzheimer’s disease. As a result of the
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ageing European population, the number of patients
is expected to double within the next 20 years [2].
Although PD is a disease more common in older age
groups, one should keep in mind that approximately
10% of patients are affected at an age below 50 years.
PD is characterized by the triad of symptoms bradyki-
nesia, tremor and rigidity. In addition, a considerable
number of non-motor symptoms may also occur dur-
ing the course of the disease, such as gastrointestinal
and autonomic disturbances, as well as behavioural
and psychological symptoms (e.g., depression, cogni-
tive impairment). Usually, the cause of the disease is
not known (therefore idiopathic), but a smaller pro-
portion of patients (<10%) have genetic disorders. PD
symptoms are triggered by a decrease in the levels of
the messenger dopamine, which allows messages to be
sent to the parts of the brain that coordinate move-
ment, due to the death of dopamine-producing nerve
cells in the substantia nigra. With the loss of dopa-
mine-producing nerve cells, these parts of the brain
are unable to function normally, causing the symp-
toms of PD to appear. Typically, if first symptoms
occur, a loss of more than 70% of the neuronal cells
in the substantia nigra has already become obvious.
No PD is like the other and so each patient has to
fight his/her own battle. The disease starts many years
before the patient is aware of it. Currently there is no
treatment available to slow down or reverse the dis-
ease. The goal of the treatment is to reduce symptoms
with as few side effects as possible. PD does not
directly cause people to die and for the majority of
people it does not significantly affect their life expec-
tancy, although some of the more advanced symptoms
can lead to increased disability and poor health, which
can make someone more vulnerable to infection.
Thus, patients sometimes live 20 years or even longer
with the disease and need to arrange their living con-
ditions and social life accordingly. Despite little
impact on life expectancy, PD patients experience pro-
gressive disability and reduced quality of life at all
stages of the disease and at all ages. Several studies
indicate that quality of life is affected not only by the
motor symptoms of PD, but also by the non-motor
symptoms such as depression and cognitive state [3].
The cost of illness escalates as PD progresses, placing
an economic burden on the healthcare system, society
and patients themselves. According to the European
Brain Council (EBC) data for 2010, annual spend in
Europe on PD was €13.9bn, consisting of €7bn in
healthcare costs, €5.5bn in direct non-medical costs
and €1.4bn in indirect costs [1].
In the present study, we describe some of the key
issues and unmet needs along the patient’s journey,
from the challenges associated with the initial
diagnosis until the diverse complications of the late
stages of the disease. We identified three key treat-
ment gaps and describe potential solutions and best
practices to give recommendations on how to improve
care in the future. In an economic evaluation, we also
assessed the impact of closing these gaps in reducing
the burden of the disease on healthcare providers and
society in two different European Union healthcare
systems.
Methods
This study was conducted in the framework of the
‘Value of Treatment for Brain Disorders’ research
project, coordinated by the EBC [4]. The PD team of
the Value of Treatment project with patient represen-
tatives, clinical experts, health economic experts and
industry partners worked together from May 2016
until June 2017 to evaluate diagnosis and treatment
gaps in PD care in Europe. They identified best prac-
tices and solutions for better PD care models in Eur-
ope and drafted recommendations on how to
implement these solutions.
The PD working group initially undertook a care
pathway analysis to identify unmet needs and key
issues throughout the course of the disease which pre-
vent PD patients from receiving adequate and timely
treatment. The main challenges and patient needs
along the care process were described and analysed
based on information from literature (review) and case
studies, as well as from consultations with both
patients and healthcare providers.
Secondly, an economic evaluation was performed to
estimate the economic benefit of timely, adequate, and
adherence to PD treatment. The aim of the economic
case study analyses proposed by the Value of Treat-
ment project was to make more and better economic
evidence on the value of treatment in brain disorders
available to policy decision-makers. The analyses were
built on previously published research in the field,
particularly where it generated evidence on effective-
ness, and used methods successfully employed in pub-
lished studies to explore the economic case for closing
treatment gaps in brain disorders (more details on the
Value of Treatment project methodology in [4]).
The economic evaluation focused on three topics
that were identified as major gaps in the care pathway
analysis: (i) lack of early/timely treatment (caused by
delayed or inadequate diagnosis); (ii) lack of adequate
treatment, and (iii) lack of adherence to treatment.
The type of evidence available varied across the three
topics considered and therefore influenced the type of
analyses conducted. Two separate healthcare systems,
in Germany and the United Kingdom (UK), were
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chosen as examples of European nations with different
healthcare systems, considering the delivery of
services, financing and coverage (details on the differ-
ences between healthcare systems are summarized in
Appendix 1 in Data S1). They were also taken as case
studies reporting on relevant evidence in the literature
that could be used for the purposes of our analyses.
Lack of early/timely treatment
The first economic analysis looked at the short term
cost-effectiveness gains attached to treatment start at
different stages in the patient journey (graded according
to Hoehn and Yahr (H&Y) stages [5]) compared with
no treatment. Published economic and QALY data for
different H&Y stages [5] were used to create a matrix
that enabled annual direct costs to be attached [6–8]
(Fig. 1). With a decision analytical modelling approach,
we evaluated the impact of a hypothetical treatment
(with fixed gain in effectiveness compared with no treat-
ment, as per published data on early PD interventions
[9,10] when given to patients in different health states
[5]. Annual direct cost estimates were reported from a
healthcare provider perspective [6] (inflated to 2017 fig-
ures from the European Central Bank Eurosystem [11],
in Euros). Effectiveness was expressed in terms of qual-
ity-adjusted life-year (QALY) gains. Cost-effectiveness
was reported in terms of incremental cost-effectiveness
ratio (ICER). Sensitivity analyses were applied to test
the robustness of the model according to variation in
the QALY improvements (0.05, 0.10 and 0.15 QALYs)
and intervention costs (€0 up to €6 daily). The analyses
included data sourced from both German [6] and UK
settings [7].
Lack of access to adequate treatment for advanced
Parkinson’s disease
A second set of analyses evaluated the cost-effective-
ness of best treatment in advanced PD (deep brain
stimulation [DBS] and best medical treatment [BMT])
compared with current care. The analysis looked at
direct costs (2017 figures from [11], in Euros) and
QALYs comparing a current scenario where only a
small proportion of eligible patients receive best treat-
ment (2% on DBS + BMT vs. 88% on BMT vs. 10%
no treatment), with a target scenario where a larger
number of patients receive best treatment (15% on
DBS + BMT vs. 85% on BMT only). Input from the
Expert Working Group was crucial to agree the deci-
sion analytical mode structure as well as the current
(suboptimal) and target model of care (Fig. 2). Pub-
lished economic evidence representing clinical progres-
sion and capturing treatment effect (QALY) and costs
using Markov modelling techniques were used to pro-
vide long-term (5-year) cost and QALY evidence for
two different healthcare settings (Germany [12] and
the UK [13], discount rates 3% and 3.5% per annum,
respectively). Appendix 2 in Data S1 provides the
patient-level cost and effectiveness data estimates con-
sidered for the different treatment options (BMT,
DBS + BMT, no treatment). Details of the Markov
models are presented elsewhere [12,13,14].
Lack of adherence to drug treatment
A third set of analyses looked at the economic impact
of adherence to treatment (e.g., looking at the change
in average patient healthcare costs according to level
of adherence); and of a shift towards increased adher-
ence to treatment in the country-specific PD patient
population. Using a decision analytical model (Fig. S3
in Data S1), we calculated the economic savings (2017
figures from [11], Euros) when moving from current
(suboptimal) to a target care scenario, with improved
adherence rates. Outcomes for the economic evalua-
tion were healthcare costs (medication costs, accident
and emergency department visits, hospitalizations,
general practitioner [GP] visits, day care and care
home stay). The perspective adopted was for the pub-
lic health insurance (Germany) and National Health
Service (NHS; UK). A timeframe of 18 months was
considered for analysis to cover the same period con-
sidered by relevant published literature. Sensitivity
analyses looked at grouping patients according to dif-
ferent definitions of adherence as follows:
• Duration of therapy: assesses the duration, or per-
sistence that a patient is treated with atypical
Parkinsonism disorders. Duration of therapy was
measured as the number of days between the first
and last filled prescription of all PD drugs and the
days’ supply of the last fill, the date of death, or the
end of 19 months or whichever came first.
• Medication possession ratio: assesses how regularly
patients take anti-PD drugs while in their possession.
Calculated as the total days’ supply for all drug
classes (numerator) divided by the aggregate duration
of therapy of all drug classes (denominator).
Use-of-resources data were extracted from previous
publications ([15–17] Appendix S3 and S1 in Data
S1]. Unit costs for Germany and UK were sourced
elsewhere ([18–23]; Appendix S3 and S4 Data S1). A
public health insurance perspective for Germany and
an NHS perspective for the UK were adopted. With
the support of the experts we adapted findings and
updated model variables using fresh evidence to reflect
what could be expected in Europe today, at today’s
prices.
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Finally, potential solutions, best practices and pol-
icy recommendations (on how to improve the situa-
tion of the patients and caregivers and how to
optimize the use of available resources) emerged from
the care pathway analysis and economic evaluation,
and were extracted from consensus reports of the
European Parkinson’s Disease Association.
Results
Care pathway analysis/patient journey narrative
The author group undertook a structured discussion
on currently felt treatment gaps during in-person
meetings. This resulted in the following main issues.
The economic analyses below were focused on these
treatment gaps.
Delayed or inadequate diagnosis and misdiagnosis
Barriers to optimal treatment are numerous. Nearly a
third of all patients who notice first symptoms wait 12
months or more before seeking medical help [24]. Fur-
thermore, long waiting times to see a PD expert also
contribute to delay in diagnosis. Although, the symp-
toms of PD are well known, the issue of missed or
mis-diagnosis is relevant as well [24] for several rea-
sons, including delay in improvement for the patient.
There is evidence showing that nearly half of diag-
noses (47%) are incorrect when performed in the pri-
mary care setting [24]. This high percentage might be
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Figure 1 Lack of early/timely treatment: economic impact of a hypothetical early/timely treatment with a fixed 0.10 quality-adjusted
life-year (QALY) gain when given to patients in different health states. Starting QALY of 0.70–0.75: a gain of 0.10 to 0.80–0.85
QALYs is accompanied by a saving of Euro €3718 (Germany) and Euro €181 (UK). Starting QALY of 0.40–0.45: a gain of 0.10 to
0.50–0.55 QALYs is accompanied by a saving of €1028 (Germany) and €5997 (UK). Starting QALY of 0.25: a gain of 0.10 to 0.35
QALY is accompanied by a saving of €5424 (Germany) and €7600 (UK). Cost-saving when providing early/timely treatment to one
patient (public providers’ perspective for 1-year time frame).
0 € 10 00 000 € 20 00 000 € 30 00 000 €
Germany, Adherence meausure: DOT
Germany, Adherence meausure: MPR
UK, Adherence meausure: DOT
UK, Adherence meausure: MPR
Figure 2 Lack of adherence to drug treatment: economic impact of improving the rates of adherence (from current suboptimal care to
best care as presented in Fig. S3). The overall cost saving for 1000 patients was considered using a public providers’ perspective for a
1-year time frame. Cost-saving for 1000 patients (with different levels of adherence as presented in Fig. S4). DOT, duration of therapy;
MPR, medication possession ratio.
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explained by the extremely diverse range of non-motor
symptoms and the fact that many symptoms are com-
mon to other diseases too. The absence of well-estab-
lished biomarkers also increases the risk of
misdiagnosis. As the deterioration in quality of life is
already significant in the early phase of the disease,
the diagnosis should be given as early as possible.
Lack of access to adequate treatment
The treatment of each patient needs to be adopted
individually and tailored carefully to patient needs
and disease stage. In the beginning, the medication
helps to control the symptoms (this initial phase is the
so-called ‘honeymoon’ phase), but these positive
effects wane from year to year. No disease-modifying
therapies are currently available. The impact of the
disease increases over time and, in the advanced stage,
PD may lead to a considerable loss of quality of life,
disability and care dependency. Recommended thera-
pies in more advanced disease stages, although only
for selected patients, include DBS and pump thera-
pies. Access to these therapies, however, is quite lim-
ited in some European countries.
Treatment of non-motor symptoms, such as depres-
sion, pain and other symptoms, should be focused on
PD care as well, as they have a major impact on the
patient’s quality of life [25]. Patients’ perceptions of
symptoms often differ from the clinician’s view, which
may have an impact on their effective management of
PD. Most patients depend on the help of their part-
ners, families and/or the support of healthcare profes-
sionals (PD is often called a ‘family’s disease’) and the
burden to them is extremely high compared to other
non-neurological chronic disorders [26]. Patients in
Central and Eastern Europe especially often feel left
alone with their problems, from the time of diagnosis
to the later stages of the disease, when carers seem to
be ignored or excluded from the decision-making pro-
cess.
Lack of adherence to drug treatment
Patients with PD, in general, seem to have poor
adherence to prescribed therapies, which is not only
critical for their well-being, but also costly for the
health system. Reasons for this non-adherence might
be the fear of secondary effects, existing comorbidities
and the complexity of dosing schedules, especially in
patients with cognitive deficits [24].
Economic evaluation
The purpose of the economic analysis was to measure
the economic impact of closing the current treatment
gaps in PD, with particular attention given to
providing timely and optimal care to PD patients. In
particular, we have focused on three major topics.
Lack of early/timely treatment
Our model suggests that, at 1 year, the hypothetical
PD treatment intervention is cost-effective regardless
of the initial health state of the patient receiving the
treatment (Germany cost savings between €1,000
and €5,400 with 0.10 QALY gain per patient; UK
cost saving of €1,800 and €7,600 with 0.10
QALY gain per patient; Fig. 1). When the treatment
enables the patient to improve to a less severe H&Y
stage (e.g., transitions from H&Y stage 2 to 1, from
stage 3 to 2 or from stages 4/5 to 3), it was found
to be not only a more effective but also less costly
option (compared to no treatment; Fig. S2). The
cost savings increased with the severity of the dis-
ease (e.g., the transition from H&Y stage 4/5 to 3)
were more cost saving than from H&Y stage 3 to 2
(e.g., €5,400 vs. €1,030 as the economic impact
of 0.10 QALY gain in Germany; €7,600 vs.
€6,000 as the economic impact of 0.10 QALY gain
in UK). If we extrapolate the study findings to a
long period (5 years or more) we can anticipate that
timely/early intervention practices would enable the
reduction of disease symptoms and related societal
and healthcare costs across healthcare systems. Sen-
sitivity analyses (Appendix 5 in Data S1) showed
that the treatment remains cost–effective within the
National Institute for Health and Care Excellence
(NICE) thresholds (or cost-saving when shifting
between H&Y stages) even in the worst scenario
(with the costliest intervention option). When dou-
bling or tripling the treatment effectiveness from
0.05 to 0.10 or 0.05 to 0.15, the window of opportu-
nity to move to a less severe H&Y stage increased
proportionally. The findings were consistent across
healthcare systems. If we extrapolate the results to
model the economic impact of early/timely treatment
to a longer period (5 years or more) we can antici-
pate that such practices would enable a decrease in
the related societal and healthcare costs across
healthcare systems.
Lack of access to adequate treatment for advanced
Parkinson’s disease
Results showed that making the adequate treatment
available to more patients is cost-effective (ICER
€15,000 to €32,600 across country settings), where an
increase in direct costs is accompanied by a gain in
QALYs (compared with current care; Table 1;
Fig. S2; Table S1). Sensitivity analyses are reported
elsewhere (Dams et al. 2013 [12], Eggington et al.
2014 [13], McIntosh et al. 2016 [14]).
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Lack of adherence to drug treatment
Results showed that, over a time frame of 1.5 years,
low levels of adherence would correspond to an increase
in annual patient costs (an increase of 20%–40% in
Germany and 80%–300% in the UK, depending on the
definition of adherence used; Figs. S3 and S4; Fig. 2).
Intensified use of hospital and residential/nursing care
home services were the main drivers of such increases.
Meeting the target adherence to treatment rates (de-
fined by the experts) would generate a cost saving of
€239.000–€576,000 (Germany) and €917,000–€
2,980,000 (UK) for every 1,000 patients treated ade-
quately. Sensitivity analyses according to different levels
of adherence are reported in Appendix 5 in Data S1.
The major voice if saving were hospitalization, day care
at home and residential/nursing home.
Discussion
The EBC provided an exact calculation of the costs
attributable to the care of brain disorders and espe-
cially PD in the different European healthcare settings
in previous publications [1,27,28]; a total of €13,9bn is
spent on the care of patients with PD in the European
Union [3]. The present study concerns the major cost
drivers based on the specific needs of the patients
identified in the patients’ journey. We have focused on
three major topics: lack of early/timely treatment
(caused by delay or inadequate diagnosis); lack of
adequate treatment; and lack of adherence to treat-
ment. The analyses confirmed that a timely, adequate
and adherent approach to PD treatment is paramount
to reducing the risk of disease progression; limiting
the effects of PD on quality of life; and tackling the
economic impact on service providers across health-
care systems.
It is important to note that the data presented in
this study are based on the limited economic evidence
available to describe the impact of the three treatment
gaps of interest in Europe (lack of early/timely treat-
ment: only effectiveness data were available as per
published data of early PD interventions [8,9]; lack of
access to adequate treatment for advanced PD: eco-
nomic data from previous cost-effectiveness analyses
in Germany [11] and UK [12]; and lack of adherence
to drug treatment: use-of-resources data were
extracted from previous publications in the US setting
[13–16]). Expert opinion was crucial to adapt the pub-
lished data to current European Union clinical path-
ways and fill possible gaps in the analyses. The time
frames considered for the three analyses were short
term (1 year) up to medium term (up to 5 years,
depending on the specific topic and evidence
retrieved). The data showcased the impact of closing
the treatment gaps on the healthcare providers in two
different healthcare systems; more evidence would be
needed to analyse the long-term consequences for
healthcare providers and society across country sys-
tems.
Evidence from the qualitative analysis of the PD
patient journey emerging from the Value of Treatment
project confirmed that barriers to optimal treatment
across Europe are numerous and span from diagnosis
to treatment of the disease and its follow-up.
Although the majority of patients with PD are in the
older age groups, to close such gaps these patients
should be actively involved in treatment decisions and
receive sufficient attention to their quality-of-life con-
cerns and specific needs. This will help identify ade-
quate treatment of the individual symptoms and
reduce the potential side effects of PD medication.
Better information and empowerment of patients will
lead to increased treatment adherence, especially if the
carers are also involved. New techniques might sup-
port the patient to identify the best individual treat-
ment.
Table 1 Second gap addressed: lack of access to adequate treatment for advanced Parkinson’s disease
Country
(source of data) Scenarios
Cost per 1000
people (5 years;
Euros, 2017)
QALY gain per
1000 people
(5 years) ICER
Germany
(Dams et al.,
2013) [12]
Target € 38 041 643 3134 €14 836
Baseline € 31 540 872 2696
UK (Eggington,
et al., 2014) [13]
Target € 64 369 795 1360 €32 681
Baseline € 54 944 966 1072
UK (McIntosh
et al., 2016) [14]
Target € 168 183 714 7145 €28 127
Baseline € 138 680 392 6096
ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year. Cost-effectiveness of best treatment (target scenario) vs. current
suboptimal care (baseline scenario). This table reports data on the cost-effectiveness of access to adequate treatment for advanced Parkinson’s
disease
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Empower patients and involve families/caregivers
Good coordination and communication among the
various healthcare providers is another important
aspect, which leads to high patient and carer satisfac-
tion. Studies from several European countries reveal
considerable differences between the existing health-
care systems and identify that the creation of multidis-
ciplinary care systems is still a long way off. However,
the Netherlands and Israel have already established
integrated, multidisciplinary care models which focus
on the patient’s needs and could serve as examples for
other countries [29,30].
Promote a multidisciplinary approach involving all
concerned parties
Patients with PD in the advanced stages of the disease
may benefit from a team effort including neurologists,
GPs, occupational therapists and physiotherapists,
who may assist whenever a problem occurs. Commu-
nication and information transfer generally need to be
improved; more efficiency is not only desirable for the
patient–doctor relationship, but also for cooperation
between the different European countries. It has
already been demonstrated that this approach will
even lead to significant savings of healthcare costs,
which could, in turn, be invested in better education
and training of providers. Currently, two PD net-
works are in place in Europe: the Dutch Parkin-
sonNet [31] and the Lombard regional network [32].
Individualized treatment as well as access to new and
advanced therapies is vital
The public needs to be much better informed about
PD, its typical symptoms and the particular needs of
patients with PD. Patients should not need to worry
about stigmatization; the disease itself is more than
enough to cope with. Increasing public awareness of
PD and the needs of PD patients (including among
employers) will help not only the individual patient
but also society as a whole to identify solutions for
the increasing impact that PD has on health and eco-
nomic systems in Europe [33–35].
Raise disease awareness and promote research
Parkinson’s disease has many different facets, which
require the joint effort of all stakeholders. Decision-
and policy-makers need to realize that they have to
act now to adequately face the ’tide’ of the upcoming
high occurrence of brain disorders so as not to be
drowned. More funding for research is needed at
different levels, including basic science, disease-ori-
ented research, and healthcare research. Funding allo-
cation to brain disorders is not adequate, and is
considerably lower compared to that for other, non-
neurological, disorders, such as cancer [25,36]. The
US Institute of Medicine panel, as well as European
governmental institutions, proposed the concept that
the amount of disease-specific research funding should
be systematically and consistently allocated depending
on the prevalence, impact of the disease on the popu-
lation and the economy of the respective society [37].
These aims have not yet been reached.
In conclusion, decision- and policy-makers are
asked to act soon in order to face the financial and
societal burden resulting from an increasing number
of patients with PD in Europe. Our analyses con-
firmed that timely and adequate treatment, and adher-
ence to this, are pivotal to improve care of the
patients and secure cost-effective care delivery across
healthcare systems. A good balance is needed between
cost-effectiveness of PD diagnosis and treatment and
the well-being of the individual with the disease.
Because of the high complexity of the disease, better
knowledge and well-coordinated care models are
needed as are already available in some countries in
Europe. The support of politicians is requested to
broadly implement available solutions and known best
practices in all European member states.
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Additional Supporting Information may be found in
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Data S1. Figure S1. First gap addressed: Lack of
timely treatment - Annual direct costs and QALYs
according to the severity of the disease. Note: German
annual costs per patient included: inpatient care (hos-
pital and rehabilitation), outpatient care, antiparkin-
sonian drugs, formal and informal carer costs, patient
co-payments, special equipment [3]. UK annual costs
per patient included: hospital outpatient and inpatient
visits, GP visits and home visits by other health pro-
fessionals, all drugs, formal and informal carer costs,
Patient co-payments, social services (home help/sup-
port, meals on wheels, sitting services, day centre, or
other specified costs) and financial benefits [7]. EQ5D
data for Germany and UK were sourced from Schrag
A et al 2000 [8].
Figure S2. Second gap addressed: Lack of access to
adequate treatment for advanced PD (decision tree)
Note: deep brain stimulation (DBS) and best medical
treatment (BMT); national health system (NHS);
Quality-adjusted life year (QALY) (a) Baseline sce-
nario (current suboptimal care). Note: deep brain
stimulation (DBS) and best medical treatment (BMT);
national health system (NHS); Quality-adjusted life
year (QALY). Note: deep brain stimulation (DBS)
and best medical treatment (BMT); national health
system (NHS); Quality-adjusted life year (QALY).
Note: Duration of therapy (DOT) it assesses the dura-
tion of time, or persistence that a patient is treated
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with Atypical Parkinson’s Disorders (APDs). DOT
was measured as the number of days between the first
and last filled prescription of all PDs and the days’
supply of the last fill, date of death, or the end of 19
months or whichever came first. Medication Posses-
sion Ratio (MPR) it assesses how regularly patients
take APDs while in their possession. Calculated as the
total days’ supply from all APD classes (numerator)
divided by the aggregate DOT of all drug classes (de-
nominator). Duration of therapy (DOT): Low DOT
was defined as 400 days, moderate DOT, 401–539
days, and high DOT, 540–548 days; Medication
Possession Ratio (MPR): Low MPR was defined as
0.80, moderate MPR, 0.80–0.89, high MPR, 0.90-0.99,
and optimal MPR,1.00.
Figure S3. Third gap addressed: lack of treatment
adherence to drug treatment (decision tree) Note:
Duration of therapy (DOT) it assesses the duration of
time, or persistence that a patient is treated with
Atypical Parkinson’s Disorders (APDs). DOT was
measured as the number of days between the first and
last filled prescription of all PDs and the days’ supply
of the last fill, date of death, or the end of 19 months
or whichever came first. Medication Possession Ratio
(MPR) it assesses how regularly patients take APDs
while in their possession. Calculated as the total days’
supply from all APD classes (numerator) divided by
the aggregate DOT of all drug classes (denominator).
Duration of therapy (DOT): Low DOT
Figure S4. Third gap addressed: lack of adherence to
drug treatment. Total costs for 1000 patients from the
public providers’ perspective (2017 Euros, 1.5 years of
treatment). Note: Duration of therapy (DOT) it
assesses the duration of time, or persistence that a
patient is treated with Atypical Parkinson’s Disorders
(APDs). DOT was measured as the number of days
between the first and last filled prescription of all PDs
and the days’ supply of the last fill, date of death, or
the end of 19 months or whichever came first. Medi-
cation Possession Ratio (MPR) it assesses how regu-
larly patients take APDs while in their possession.
Calculated as the total days’ supply from all APD
classes (numerator) divided by the aggregate DOT of
all drug classes (denominator).
Appendix 1. Main differences between the British and
the German health care systems.
Appendix 2. Lack of access to adequate treatment for
advanced PD – Patient-level cost and effectiveness
data estimates per alternative considered Note:
Extrapolated from yearly estimates from Olanow
2014; yearly discount of 3.5% was applied. QALYs =
quality adjusted life years; BMT = best medical
treatment; DBS+MT = deep brain stimulation and
best medical treatment.
Appendix 3. Lack of treatment adherence to drug
treatment - prevalence, adherence, and use of
resources.
Appendix 4. Lack of treatment adherence to drug
treatment - unit costs.
Appendix 5. Sensitivity analyses. Gap 1: Lack of
early/timely treatment- German results.
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